GRCE Grace Therapeutics, Inc.
$2.38 +6.97%
Healthcare · Pharmaceutical Preparations
Grace Therapeutics, Inc. (GRCE) is a healthcare company in the Pharmaceutical Preparations industry, with a market capitalization of $39 million. Shares last traded at $2.38, 53.8% below their 52-week high. Over the past year the stock is down 17.1%. Net profit margin is -7.8%, below the peer median of -0.1%.
Market Cap
$39M
Shares Out
16.3M
EPS (TTM)
$-1.78
P/E Ratio
—
P/S Ratio
0.39
P/B Ratio
0.61
Dividend / Share
—
Dividend Yield
—
52-Week High
$5.15
52-Week Low
$1.79
Volume
20,994
Avg Vol (3m)
20,928.27
Performance
1W
+3.03%
1M
+10.44%
3M
-45.54%
6M
-28.85%
YTD
-34.88%
1Y
-17.07%
Chart
Full chart →Daily candles · volume · SMA(20)/SMA(50) · Databento EQUS.MINI.
Technicals
RSI (14)
48.14
SMA (50)
$2.69
SMA (200)
$3.30
Price vs SMA50
-11.39%
Price vs SMA200
-27.97%
ATR (14)
$0.15
Financials
Revenue
$100M
Net Income
$-8M
Gross Margin
—
Operating Margin
-11.1%
Net Margin
-7.8%
Return on Equity
-12.2%
Return on Assets
-11.7%
Current Ratio
8.10
Debt / Equity
0.04
Revenue Growth (YoY)
—
Latest reported annual period ending 2022-03-31 · SEC EDGAR/XBRL.
Recent earnings
| Period | EPS (diluted) | Reported |
|---|---|---|
| FY 2026 | $-0.47 | 2026-06-18 |
| Q3 2026 | $-0.41 | 2026-02-12 |
| Q2 2026 | $-0.27 | 2025-11-13 |
| Q1 2026 | $-0.21 | 2025-08-12 |
| FY 2026 | $-0.79 | 2026-06-18 |
| Q3 2026 | $-0.89 | 2026-02-12 |
Pharmaceutical Preparations peers
GRCE vs 14 industry peers (Pharmaceutical Preparations), by market cap.
P/S vs peers
0.39 / 3.54 med
-89% discount
Net margin vs peers
-7.8% / -0.1% med
below median
1–14 of 14
| LLY | Lilly (Eli) | $1.04T | 50.16 | 15.88 | 31.7% | -1.17% |
| JNJ | Johnson & Johnson | $549.8B | 20.51 | 5.84 | 28.5% | -2.42% |
| ONC | Beone Medicines Ltd. | $390.6B | 1361.26 | 73.10 | 5.4% | +2.83% |
| ABBV | AbbVie | $382.5B | 90.51 | 6.25 | 6.9% | -2.16% |
| MRK | Merck | $281.6B | 15.43 | 4.33 | 28.1% | -1.30% |
| ABT | Abbott Laboratories | $154.3B | 23.65 | 3.48 | 14.7% | +0.09% |
| PFE | Pfizer | $143.7B | 18.50 | 2.30 | 12.4% | -2.89% |
| VRTX | Vertex Pharmaceuticals | $114.6B | 28.99 | 9.55 | 32.9% | -1.63% |
| BMY | Bristol Myers Squibb | $110.3B | 15.63 | 2.29 | 14.6% | -2.35% |
| REGN | Regeneron Pharmaceuticals | $63.4B | 14.08 | 4.42 | 31.4% | +0.38% |
| ALNY | Alnylam Pharmaceuticals | $36.9B | 117.57 | 9.93 | 8.4% | -1.66% |
| TEVA | Teva Pharmaceutical Industries Ltd | $36.6B | 25.98 | 2.12 | 8.2% | -3.33% |
| ZTS | Zoetis | $33.1B | 12.37 | 3.49 | 28.2% | +2.09% |
| RPRX | Royalty Pharma Plc | $23.1B | 30.02 | 9.73 | 32.4% | -1.30% |
Source: SEC EDGAR (fundamentals/EPS/dividends) · Databento EQUS.MINI (prices) · market cap & yield computed by tradmap. Informational only — not financial advice.